An Open-Label, Non-Randomized, Single-Center Study to Determine the Absorption, Metabolism and Excretion of A Single Dose [14C] AC0010 in Patients With Advanced NSCLC
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Abivertinib-maleate (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 07 Sep 2017 Status changed from recruiting to completed.
- 26 Jun 2017 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017.
- 26 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017.